Minocycline (Minolexin®) clinical efficacy and tolerability evaluation in women with bacterial-associated chronic cervicitis

Yu.E. Dobrokhotova1, I.N. Kononova1,2, E.N. Kareva1,3, N.A. Shmakova4, I.V. Graban5, T.A. Ogurtsova6 1Pirogov Russian National Research Medical University, Moscow, Russian Federation 2LLC "Interregional Center for Continuing Professional Education", Moscow, Russian Federation 3I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation 4LLC Medical Center "ANGIO LINE PLUS", Yekaterinburg, Russian Federation 5LLC Medical Center "Edelweiss", Aramil, Russian Federation 6Yekaterinburg Clinical Perinatal Center, Yekaterinburg, Russian Federation Background: bacterial-associated chronic cervicitis (CC) occupies a leading place in the cervical pathology structure. At the same time, the disease recurrence rate reaches 59–68% in the setting of resistance to antibacterial therapy, which determines the need to find new effective drugs. Aim: to evaluate the clinical efficacy, safety and compliance of therapy with minocycline in patients with bacterial-associated CC. Patients and Methods: a multicenter prospective observational clinical study was conducted in women's health clinics and medical centers in Yekaterinburg. The study included 60 female patients with a confirmed diagnosis of bacterial-associated CC. Group 1 (n=31) received the antibacterial drug minocycline (Minolexin®) 100 mg twice a day in the morning and evening, 10 days + antimycotic prebiotic 1 suppository once a day intravaginally for 6 days, starting from the 3rd day of antibiotic therapy. Group 2 (n=29) received doxycycline 100 mg twice a day for 10 days + antimycotic prebiotic 1 suppository once a day intravaginally for 6 days, starting from the 3rd day of antibiotic therapy. Clinical and laboratory efficacy (cervicitis signs, results of laboratory microbiome research methods) and drug tolerability were evaluated 10 and 30 days after the treatment initiation. Results: as a result of CC antibacterial therapy with minocycline, pathogen eradication was observed in 83.9% of female patients (group 2 — in 69.9%, p=0.0001), the original squamous epithelium 30 days after the minocycline was detected in 27 (87.1%) female patients (group 2 — in 19 (65.5±5.8%) female patients, p=0.0001), which indicates a higher efficacy of minocycline versus doxycycline. Patients of the minocycline group had more therapy adherence — 96.8% vs. 82.9% in the doxycycline group (p=0.0001) due to the minimal number of side effects (3.2% vs. 17.2%, respectively; p=0.0001). Conclusion: minocycline is a systemic antibiotic of the tetracycline group, which can be considered as the front-line drug for antibacterial therapy of patients with CC due to its high clinical efficacy, minimal risk of side effects and high compliance. Keywords: chronic cervicitis, antibacterial therapy, tetracyclines, minocycline, efficacy. For citation: Dobrokhotova Yu.E., Kononova I.N., Kareva E.N., Shmakova N.A., Graban I.V., Ogurtsova T.A. Minocycline (Minolexin®) clinical efficacy and tolerability evaluation in women with bacterial-associated chronic cervicitis. Russian Journal of Woman and Child Health. 2023;6(4):340–346 (in Russ.). DOI: 10.32364/2618-8430-2023-6-4-3. <br

Evaluation of the sucrosomial iron efficacy in the patient treatment with stage 1–2 iron deficiency anemia during heavy menstrual bleeding

I.N. Kononova1,2, Yu.E. Dobrokhotova1, E.N. Kareva1,3, N.A. Shmakova4, I.V. Graban5, T.A. Ogurtsova6 1Pirogov Russian National Research Medical University, Moscow, Russian Federation 2Transregional Center for Continuing Professional Education LLC, Moscow, Russian Federation 3I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation 4Medical Center "Angio Line plus" LLC, Yekaterinburg, Russian Federation 5Medical Center "Edelweiss", Yekaterinburg, Russian Federation 6Yekaterinburg Clinical Perinatal Center, Yekaterinburg, Russian Federation Aim: to evaluate the clinical efficacy of Sucrosomial® iron (SiderAL® Forte) in the treatment of stage 1–2 iron deficiency anemia (IDA) in patients with menorrhagia in the setting of ovulation disorders. Patients and Methods: a prospective randomized multicenter clinical case study of 110 patients with stage 1–2 IDA developed in the setting of menorrhagia as a result of ovulation disorders was conducted. Female patients of the main group (n=74) received Sucrosomial® iron 30 mg 2 times a day for 60 days. In the control group (n=36), a liposomal iron preparation of 30 mg 2 times a day was also prescribed for 60 days. Results: during Sucrosomial® iron ferrotherapy, an increase in Hb levels by more than 20 g/L was observed after 30 days of administration in 65 (87%) female patients, after 60 days in 73 (98.6%) female patients, which demonstrated higher therapeutic efficacy versus liposomal iron preparation (69.4 and 88.8%, respectively, p=0.0001). There was also a greater adherence to therapy (98.6%) during Sucrosomial® iron intake versus liposomal iron intake (86.1%, p=0.0001), due to fewer (1.4%) adverse events compared with the control group (5.5%, p=0.0002). Conclusion: oral ferrotherapy with Sucrosomial® iron is a reasonable option for the IDA treatment in patients with menorrhagia due to its higher efficacy versus the liposomal iron. The effect occurs after 30 days of drug intake with a minimum number of adverse events, due to the unique structural, physico-chemical and pharmacokinetic characteristics of the sucrosomial iron, thanks to which it is protected from the gastric juice action, does not contact with the gastrointestinal mucosa and is absorbed through special intestinal M-cells with further iron release in liver cells. Keywords: iron deficiency anemia, menorrhagia, ovulation disorders, Sucrosomial® iron, women, therapy. For citation: Kononova I.N., Dobrokhotova Yu.E., Kareva E.N., Shmakova N.A., Graban I.V., Ogurtsova T.A. Evaluation of the sucrosomial iron efficacy in the patient treatment with stage 1–2 iron deficiency anemia during heavy menstrual bleeding. Russian Journal of Woman and Child Health. 2023;6(4):332–339 (in Russ.). DOI: 10.32364/2618-8430-2023-6-4-2. <br

ПЕРВЫЕ ШАГИ В НАУЧНО-ПОПУЛЯРНОМ КОНТЕНТЕ: МИНИ-ПРИЛОЖЕНИЕ «КОПЕРНИК» КАК СРЕДСТВО РАЗВИТИЯ СТУДЕНЧЕСКИХ НАУЧНЫХ ОБЩЕСТВ

Students' science is one of the most important factor of progress in the field of the formation of scientific personnel. Young scientists are trying to start research from the university bench, but they face insurmountable difficulties, lack of information and experience. As a solution to the problem, we propose the project “Kopernik” by name, a multimedia platform for ensuring the interaction of students' scientific societies and undergraduate students.Студенческая наука - один из двигателей прогресса в области формирования научных кадров. Молодые ученые уже с университетской скамьи пробуют проводить исследования, но сталкиваются с непреодолимыми сложностями, недостатком информации и опыта. В качестве решения проблемы мы предлагаем проект «Коперник» - мультимедийную площадку для обеспечения взаимодействия студенческих научных обществ, абитуриентов и студентов младших курсов

Assessment of the efficacy and compliance with Vojea® in women during the pregravid preparation and the early stages of pregnancy

I.N. Kononova1,2, E.N. Kareva1,3, E.V. Stebenyaeva4, N.A. Shmakova5, I.V. Graban6, T.A. Ogurtsova7, Yu.E. Dobrokhotova1, S.V. Orlova8 1Pirogov Russian National Research Medical University, Moscow, Russian Federation 2LLC "Interregional Center for Continuing Professional Education", Moscow, Russian Federation 3I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation 4LLC "SMARTLAB", Yekaterinburg, Russian Federation 5LLC Medical Center "ANGIO LINE PLUS", Yekaterinburg, Russian Federation 6LLC Medical Center "Edelweiss", Aramil, Russian Federation 7Yekaterinburg Clinical Perinatal Center, Yekaterinburg, Russian Federation 8Russian University of Peoples' Friendshiр, Moscow, Russian Federation Aim: to assess the clinical efficacy, safety and tolerability of Vojea® in the prevention of iron-deficiency anemia and folic acid deficiency in women during the preconception (pregravid) period and early stages of pregnancy, as well as to evaluate patient compliance with this product. Patients and Methods: this prospective multi-center observational study was performed in 2022 in four medical centers and women's health clinics of Ekaterinburg. The study included 87 women with latent iron deficiency (mean ferritin level below 15 ng/ml). The first group consisted of 37 women during the pregravid preparation period, and the second group consisted of 50 pregnant patients with up to 12 weeks of pregnancy. Patients received the Vojea® once daily for three months. Clinical and laboratory efficacy (the absence of objective anemia signs and the changes in hemoglobin level, folate and ferritin blood tests over time), as well as tolerability (the rate of adverse events, tolerability of the taken product evaluated using the visual analog scale) was assessed at days 30, 60 and 90 after the beginning of treatment. Results: beginning from the first month of treatment with the studied complex, some positive changes in clinical symptoms and laboratory findings were reported in both groups. By the third month of therapy, the increment of hemoglobin level in the pregravid preparation group was 17 (13.9%) units, the level of ferritin increased by 6.3 times (clinically significant after two months of the product intake), and the level of blood serum folates increased by 4.6 times. In group 2, the increment of hemoglobin level, as pregnancy was progressing, in three months of the product intake reached 19 units (17%), the level of ferritin increased by 5.9 times (clinically significant after two months of treatment), and the level of blood serum folates increased by 3.9 times. In group 1, adverse events were reported only in 2/37 (5.4%) patients who had dark stool color on the 2nd month of follow-up. In group 2, such adverse events as nausea were reported in 3/50 (6%) patients during the 1st month of product intake. All patients informed that the product was well tolerated which ensured high patient compliance. Conclusion: maintaining iron and folic acid homeostasis by oral intake of the Vojea® complex during three months in the preconception period and early stages of pregnancy is a feasible option based on its high efficacy and good tolerability with the minimal risk of side effects, encouraging high patient compliance. Keywords: ferric pyrophosphate, folic acid, pregravid preparation, pregnancy, active metabolite of folic acid, methyltetrahydrofolate, glucosamine salt, Quatrefolic, micronized microencapsulated ferric iron, Vojea, compliance. For citation: Kononova I.N., Kareva E.N., Stebenyaeva E.V. et al. Assessment of the efficacy and compliance with Vojea® in women during the pregravid preparation and the early stages of pregnancy. Russian Journal of Woman and Child Health. 2023;6(2):95–104 (in Russ.). DOI: 10.32364/2618-8430-2023-6-2-95-104. </p